M&A Deal Summary

Saol Therapeutics Acquires Aptevo Therapeutics - Hyperimmune Commercial Products

On August 31, 2017, Saol Therapeutics acquired medical products company Aptevo Therapeutics - Hyperimmune Commercial Products from Aptevo Therapeutics for 75M USD

Acquisition Highlights
  • This is Saol Therapeutics’ 1st transaction in the Medical Products sector.
  • This is Saol Therapeutics’ largest (disclosed) transaction.
  • This is Saol Therapeutics’ 1st transaction in the United States.
  • This is Saol Therapeutics’ 1st transaction in Washington.

M&A Deal Summary
Date 2017-08-31
Target Aptevo Therapeutics - Hyperimmune Commercial Products
Sector Medical Products
Buyer(s) Saol Therapeutics
Sellers(s) Aptevo Therapeutics
Deal Type Divestiture
Deal Value 75M USD

Target

Aptevo Therapeutics - Hyperimmune Commercial Products

Seattle, Washington, United States
Aptevo Therapeutics, Inc. - Hyperimmune Commercial Products comprises WinRho SDF, HepaGam B, and VARIZIG. WinRho SDF for autoimmune platelet disorder and hemolytic disease of the newborn; HepaGam B for the prevention of Hepatitis B following liver transplantation and for treatment following hepatitis B exposure; and VARIZIG for treatment following exposure to varicella zoster virus for individuals with compromised immune systems.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Saol Therapeutics

Roswell, Georgia, United States
Category Company
Founded 2015
Sector Life Science
DESCRIPTION

Saol Therapeutics is a privately held specialty pharmaceutical company focused on providing therapies to patients with rare diseases. Saol Therapeutics has a strategic emphasis on the neurology therapeutic area. Saol Therapeutics was founded in 2015 and is based in Roswell, Georgia.

DEAL STATS #
Overall 1 of 1
Sector (Medical Products) 1 of 1
Type (Divestiture) 1 of 1
State (Washington) 1 of 1
Country (United States) 1 of 1
Year (2017) 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-01-06 Saol Therapeutics - Baclofen Franchise

Roswell, Georgia, United States

Saol Therapeutics' Baclofen Franchise is a pipeline product under development. Lioresal® is an intrathecal baclofen product delivered through an implantable intrathecal pump for use in the management of severe spasticity of cerebral or spinal origin for the institutional market. LYVISPAHTM is a baclofen oral granules (5, 10, and 20 mg) specialty product recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of spasticity.

Sell -

Seller(S) 1

SELLER

Aptevo Therapeutics

Seattle, Washington, United States
Category Company
Founded 2016
Sector Life Science
DESCRIPTION

Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. Company leverage the innovative ADAPTIR platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients. Based in Seattle, Washington, the company is proud of its empowering work environment, entrepreneurial culture, and proprietary platform technology. As a result, Aptevo has been able to attract some of the most innovative minds in the field. Many of our team members have notable experience with other pioneering biotech companies including Trubion, ZymoGenetics, Immunex, Dendreon, and VLST.

DEAL STATS #
Overall 1 of 2
Sector (Medical Products) 1 of 1
Type (Divestiture) 1 of 2
State (Washington) 1 of 1
Country (United States) 1 of 2
Year (2017) 1 of 1
Size (of disclosed) 1 of 2
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-02-28 IXINITY

Chicago, Illinois, United States

IXINITY is a medicine used to replace clotting factor (factor IX) that is missing in adults and children at least 12 years of age with hemophilia B. Hemophilia B is also called congenital factor IX deficiency. Hemophilia B is an inherited bleeding disorder that prevents clotting.

Sell $30M
Mergr

Product

Company

Legal